Merial GmbH, Kathrinenhof Research Center, 83101 Rohrdorf, Germany.
Qatar University, Department of Health Sciences, College of Arts and Sciences, Doha, Qatar.
Vet Parasitol. 2014 Apr 28;202(1-2):18-25. doi: 10.1016/j.vetpar.2014.02.033.
The efficacy of a novel topical combination formulation of fipronil, (S)-methoprene, eprinomectin and praziquantel against naturally acquired intestinal nematode and cestode infections in cats was evaluated in seven negative control, blinded studies. Cats were selected based on a pre-treatment faecal examination indicating a patent infection with at least hookworms (two studies), Toxocara ascarids (one study), taeniid cestodes (two studies) or Dipylidium cestodes (two studies). In each study, cats were assigned randomly to blocks of two animals each, based on decreasing pre-treatment body weight and were randomly allocated to one of two groups of six to 12 cats: untreated (control) or treated with topical fipronil (8.3%, w/v), (S)-methoprene (10%, w/v), eprinomectin (0.4%, w/v) and praziquantel (8.3%, w/v) (BROADLINE(®), Merial) at 0.12 mL/kg body weight (providing a minimum of 10mg fipronil+12 mg S-methoprene+0.5mg eprinomectin+10mg praziquantel per kg body weight). The topical treatment was administered directly on the skin in the midline of the neck in a single spot once on Day 0. For parasite recovery and count, cats were euthanized humanely and necropsied seven or ten days after treatment. A single treatment with the novel topical combination product provided 91% efficacy against Ancylostoma braziliense, ≥ 99% efficacy against Ancylostoma tubaeforme, and >97% efficacy against Toxocara cati. Similarly, excellent efficacy was established against Taenia taeniaeformis, Dipylidium caninum and Diplopylidium spp. as demonstrated by >97% and up to 100% reductions of cestode counts in the treated cats when compared to the untreated controls (P<0.01). All cats accepted the treatment well based on health observations post-treatment and daily health observations. No adverse experiences or other health problems were observed throughout the studies. The results of this series of controlled studies demonstrated high efficacy and excellent acceptability of the novel topical combination formulation of fipronil, (S)-methoprene, eprinomectin and praziquantel against a broad range of feline intestinal nematode and cestode infections.
一种新型的非泼罗尼、（S）-灭幼脲、伊维菌素和吡喹酮的局部联合配方制剂对自然获得性猫肠道线虫和绦虫感染的疗效在七项阴性对照、盲法研究中进行了评估。根据治疗前粪便检查，选择了感染至少钩虫（两项研究）、蛔虫（一项研究）、带绦虫（两项研究）或复孔绦虫（两项研究）的猫。在每项研究中，根据治疗前的体重，将猫随机分为每组 2 只的组块，并随机分配到两组 6 至 12 只猫中的一组：未治疗（对照组）或用局部非泼罗尼（8.3%，w/v）、（S）-灭幼脲（10%，w/v）、伊维菌素（0.4%，w/v）和吡喹酮（8.3%，w/v）（BROADLINE®，默沙东）治疗，剂量为 0.12 毫升/公斤体重（提供至少 10mg 非泼罗尼+12mg（S）-灭幼脲+0.5mg 伊维菌素+10mg 吡喹酮/公斤体重）。局部治疗是在第 0 天一次性将药物直接涂于颈部中线的皮肤上。为了进行寄生虫回收和计数，在治疗后 7 或 10 天，将猫安乐死并进行尸检。单次使用新型局部联合制剂对巴西钩虫（Ancylostoma braziliense）的疗效为 91%，对管状钩虫（Ancylostoma tubaeforme）的疗效≥99%，对猫蛔虫（Toxocara cati）的疗效>97%。同样，对带绦虫（Taenia taeniaeformis）、犬复孔绦虫（Dipylidium caninum）和双孔绦虫（Diplopylidium spp.）也建立了极好的疗效，与未治疗的对照组相比，治疗猫的绦虫计数减少了>97%，高达 100%（P<0.01）。所有猫在治疗后根据健康观察和每日健康观察均表现出良好的耐受性。在整个研究过程中，未观察到不良体验或其他健康问题。这一系列对照研究的结果表明，新型非泼罗尼、（S）-灭幼脲、伊维菌素和吡喹酮的局部联合配方制剂对广泛的猫肠道线虫和绦虫感染具有高效性和极好的可接受性。
